Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension. 2018;71:530–7.

Article  CAS  PubMed  Google Scholar 

Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41–50.

Article  CAS  PubMed  Google Scholar 

Fu Y, Hall JE, Lu D, Lin L, Manning RD Jr, Cheng L, et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension. 2012;59:599–606.

Article  CAS  PubMed  Google Scholar 

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

Article  CAS  PubMed  Google Scholar 

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72:658–66.

Article  CAS  PubMed  Google Scholar 

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–9.

Article  PubMed  Google Scholar 

Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385:1737–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai C-F, group tTs. kidney function predicts new-onset cardiorenal events and mortality in primary aldosteronism: approch of the 2021 race-free eGFR equation. Hypertens Res. 2023. https://doi.org/10.1038/s41440-023-01400-0.

Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–9.

Article  CAS  PubMed  Google Scholar 

Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380:1662–73.

Article  PubMed  PubMed Central  Google Scholar 

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

Article  CAS  PubMed  Google Scholar 

Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan endocrine society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69:327–59.

Article  PubMed  Google Scholar 

Huang WC, Chen YY, Lin YH, Chueh JS. Composite cardiovascular outcomes in patients with primary aldosteronism undergoing medical versus surgical treatment: a meta-analysis. Front Endocrinol. 2021;12:644260.

Article  Google Scholar 

Saiki A, Otsuki M, Tamada D, Kitamura T, Mukai K, Yamamoto K, et al. Increased dosage of MRA improves BP and urinary albumin excretion in primary aldosteronism with suppressed plasma renin. J Endocr Soc. 2022;6:bvab174.

Article  PubMed  Google Scholar 

Yoshida Y, Fujiwara M, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, et al. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens Res. 2023. https://doi.org/10.1038/s41440-023-01412-w. Online ahead of print.